COPD Acute Exacerbation
7
1
3
1
Key Insights
Highlights
Success Rate
50% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 85/100
14.3%
1 terminated out of 7 trials
50.0%
-36.5% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 1 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (7)
The REVIVE Pivotal Study
Rademikibart Add-on Treatment of an Acute COPD Exacerbation (Seabreeze STAT COPD)
Change in Sleep Breathing During Hospital Admission for COPD Exacerbation
Kinetics and Metabolism of Nicotinamide Provided as a Dietary Supplementation
Efficacy Of Inpatient Pulmonary Rehabilitation Program In Elderly Patients With Acute Exacerbation Of COPD
CO2 Removal in Severe Acute exacerbatIons of Chronic Obstructive Lung Diseases
The Role of Nebulized Budesonide in the Treatment of Acute Exacerbations of COPD